Claim Missing Document
Check
Articles

Found 39 Documents
Search

Bartter Syndrome: A Case Report Yayik Supriyani; Deka Viotra; Putri Deas Hadilofyani
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 7 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i7.844

Abstract

Background: Bartter's syndrome refers to a group of genetic disorders that affect the renal tubular system, which is responsible for reabsorbing various substances such as sodium, potassium, and chloride from the urine into the blood. This study aimed to present a clinical case related to Bartter syndrome. Case presentation: A 52-year-old male patient in the internal medicine department of Dr. M. Djamil General Hospital Padang with the main complaint of weakness in both legs increasing since 1 day ago. On laboratory examination, the patient found potassium 1.7 mmol/L, indicating hypokalemia. Renal function examination showed normal kidney function. Examination of blood gas analysis showed results of metabolic alkalosis. Examination of urine potassium obtained potassium levels of 22 mmol/day, urine osmolarity of 140 mOsm/kgH2O at serum osmolarity of 274 mOsm/kgH2O, with TTKG (transtubular potassium gradient) = 28. The patient was diagnosed with Bartter syndrome. Treatment is carried out by administering KSR tablets 3x600 mg orally while monitoring electrolytes regularly. Conclusion: This patient has hypokalemia, metabolic alkalosis, normal magnesium and calcium, and hypercalciuria. This patient is diagnosed with Bartter syndrome.
The Role of Monocyte Chemoattractant Protein-1 (MCP-1) in Diabetic Kidney Disease Deddy Canceria Suka Rahmatsyah; Harnavi Harun; Deka Viotra
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 9 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i9.861

Abstract

Monocyte chemoattractant protein-1 plays an important role in kidney disease. In several studies, the role of MCP-1 as a urine biomarker has been extensively studied. In many kidney diseases, there are elevated levels of MCP-1 in the kidney tissue and this is an important cause of monocyte infiltration in the pathogenesis of kidney damage. Elevated urinary MCP-1 levels have been able to predict outcome in proliferative kidney diseases such as lupus nephritis. However, in several studies it was also found that there was an increase in MCP-1 in diabetic kidney disease. Macrophages have even appeared early in diabetic kidney disease and are associated with the progression of kidney disease. Urinary MCP-1 levels are related to the degree of leukocyte infiltration in the tubulointerstitial. This supports inflammatory factors as part of the pathogenesis of diabetic kidney disease.
Symmetric Dimethylarginine as a Biomarker for Chronic Kidney Disease Khairat AS; Harnavi Harun; Deka Viotra
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 9 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i9.866

Abstract

Symmetric dimethylarginine (SDMA), is a post-translationally stable catabolic product of arginine-methylated proteins that plays an important role in basic cellular metabolism. SDMA is an endogenous biomarker of kidney function that has been widely used in veterinary medicine. Symmetric dimethylarginine (SDMA) and asymmetric dimethylarginine (ADMA) are 2 constant products of L-arginine proteolysis that undergo methylation. SDMA is almost completely excreted by the kidneys after filtration making SDMA an ideal GFR biomarker candidate. Apart from that, SDMA has several advantages as a biomarker of kidney function, namely that it is not affected by non-renal factors that influence creatinine and cystatin C. Apart from that, SDMA also increases earlier than other biomarkers.
Bartter Syndrome: A Case Report Yayik Supriyani; Deka Viotra; Putri Deas Hadilofyani
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 7 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i7.844

Abstract

Background: Bartter's syndrome refers to a group of genetic disorders that affect the renal tubular system, which is responsible for reabsorbing various substances such as sodium, potassium, and chloride from the urine into the blood. This study aimed to present a clinical case related to Bartter syndrome. Case presentation: A 52-year-old male patient in the internal medicine department of Dr. M. Djamil General Hospital Padang with the main complaint of weakness in both legs increasing since 1 day ago. On laboratory examination, the patient found potassium 1.7 mmol/L, indicating hypokalemia. Renal function examination showed normal kidney function. Examination of blood gas analysis showed results of metabolic alkalosis. Examination of urine potassium obtained potassium levels of 22 mmol/day, urine osmolarity of 140 mOsm/kgH2O at serum osmolarity of 274 mOsm/kgH2O, with TTKG (transtubular potassium gradient) = 28. The patient was diagnosed with Bartter syndrome. Treatment is carried out by administering KSR tablets 3x600 mg orally while monitoring electrolytes regularly. Conclusion: This patient has hypokalemia, metabolic alkalosis, normal magnesium and calcium, and hypercalciuria. This patient is diagnosed with Bartter syndrome.
The Role of Monocyte Chemoattractant Protein-1 (MCP-1) in Diabetic Kidney Disease Deddy Canceria Suka Rahmatsyah; Harnavi Harun; Deka Viotra
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 9 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i9.861

Abstract

Monocyte chemoattractant protein-1 plays an important role in kidney disease. In several studies, the role of MCP-1 as a urine biomarker has been extensively studied. In many kidney diseases, there are elevated levels of MCP-1 in the kidney tissue and this is an important cause of monocyte infiltration in the pathogenesis of kidney damage. Elevated urinary MCP-1 levels have been able to predict outcome in proliferative kidney diseases such as lupus nephritis. However, in several studies it was also found that there was an increase in MCP-1 in diabetic kidney disease. Macrophages have even appeared early in diabetic kidney disease and are associated with the progression of kidney disease. Urinary MCP-1 levels are related to the degree of leukocyte infiltration in the tubulointerstitial. This supports inflammatory factors as part of the pathogenesis of diabetic kidney disease.
Symmetric Dimethylarginine as a Biomarker for Chronic Kidney Disease Khairat AS; Harnavi Harun; Deka Viotra
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 9 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i9.866

Abstract

Symmetric dimethylarginine (SDMA), is a post-translationally stable catabolic product of arginine-methylated proteins that plays an important role in basic cellular metabolism. SDMA is an endogenous biomarker of kidney function that has been widely used in veterinary medicine. Symmetric dimethylarginine (SDMA) and asymmetric dimethylarginine (ADMA) are 2 constant products of L-arginine proteolysis that undergo methylation. SDMA is almost completely excreted by the kidneys after filtration making SDMA an ideal GFR biomarker candidate. Apart from that, SDMA has several advantages as a biomarker of kidney function, namely that it is not affected by non-renal factors that influence creatinine and cystatin C. Apart from that, SDMA also increases earlier than other biomarkers.
Endoscopic Sphenopalatine Artery Ligation in Recurrent Epistaxis with Hypertensio Aini Zhann; Dolly Irfandy; Bestari Jaka Budiman; Deka Viotra
Majalah Kedokteran Andalas Vol 46, No 4 (2023): Online Juli 2023
Publisher : Faculty of Medicine, Universitas Andalas

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25077/mka.v46.i4.p736-744.2023

Abstract

AbstractBackground: Epistaxis is the most common case in ORL-HNS emergencies. One of the risk factors of recurrent epistaxis is hypertension. Epistaxis in hypertension usually originates from the posterior vessels. This requires more invasive procedures such as sphenopalatine artery ligation. Case Report: A 58-year-old woman with complaints of recurrent epistaxis from the right nose. The results of the blood pressure examination showed the results of 190/120 mmHg. The patient underwent sphenopalatine artery ligation to prevent recurrence. Conclusion: One of the factors for recurrent epistaxis is hypertension. Initial management of epistaxis with recurrent hypertension can be done in a conservative way followed by surgery and keeping blood pressure stable. Endoscopic sphenopalatine artery ligation is the definitive treatment according to the epistaxis management algorithm. Endoscopic sphenopalatine artery ligation provides satisfactory results and minimal complications.Keywords: Recurrent epistaxis, hypertension, sphenopalatine artery ligation
The Difference of Survival Rate COVID-19 in Patients with Initiated Hemodialysis and Regularly Hemodialysis Viotra, Deka; Harnavi Harun; Drajad Priyono; Fauzar; Roza Kurniati; Alexander Kam; Abdul Alim Rahimi; Jersivindo Ranazeri; Zaki Mahmudi Dasril
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 10 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i10.877

Abstract

Background: Since December 2019, a novel coronavirus called SARSCoV-2 (severe acute respiratory syndrome coronavirus) has caused an international outbreak of respiratory illness described as COVID-19. This study aimed to describe the difference in the survival rate of COVID-19 induced AKI with hemodialysis and COVID-19 in patients with CKD on hemodialysis in Dr. M Djamil General Hospitals. Also, in this review, we provide a comprehensive overview of data on the factors that may be affected by COVID-19 survival rates in patients with COVID-19 induced AKI with hemodialysis and COVID-19 in patients with CKD on hemodialysis. This study was conducted to analyze the survival of COVID-19 with initiated or regular HD patients in Dr. M. Djamil General Hospital, Padang, Indonesia. Methods: This study was conducted from January 2021 to July 2021 in Dr. M. Djamil General Hospital, Padang, West Sumatera, Indonesia. Data for this study was collected through medical records of patients admitted for COVID-19 with CKD in hemodialysis and acute renal failure induced by COVID-19 to show the demographics, comorbidities, and survival rates of the patients who underwent hemodialysis. Results: Factors associated with survival in COVID-19 with hemodialysis were COVID-19 severity and abnormal potassium serum level (Table 3). Moderate COVID-19 patients tend to survive than severe COVID-19 patients (OR 60; 95% CI 16.034 – 224.525). There was no significant difference in survival between initiated and regular HD (p = 0.829). Conclusion: There is no difference in clinical outcome from patients with COVID-19 who initiated hemodialysis or regularly HD to the survival rates.
Systemic Lupus Erythematosus with Lupus Nephritis, Community-Acquired Pneumonia, Bilateral Pleural Effusion, Pericardial Effusion, and Hypoalbuminemia in a 20-Year-Old Male Patient: A Case Report Pratama Yudha, Muhammad Agung; Deka Viotra; Najirman
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 8 No. 8 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v8i8.1050

Abstract

Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multisystem inflammation. Lupus nephritis is a serious complication of SLE that can cause kidney failure. Community acquired pneumonia (CAP), bilateral pleural effusion, pericardial effusion, and hypoalbuminemia are other complications that can occur in SLE patients. Case presentation: We report the case of a 20-year-old man with SLE who presented with lupus nephritis, CAP, bilateral pleural effusion, pericardial effusion, and hypoalbuminemia. Patients were diagnosed with SLE based on the American College of Rheumatology (ACR) classification criteria. The diagnosis of lupus nephritis is made based on the presence of proteinuria, hematuria, and casts on urinalysis, as well as findings on kidney biopsy. CAP is diagnosed based on the presence of fever, cough, cough with phlegm, and infiltrates on chest X-ray. Bilateral pleural effusion and pericardial effusion were diagnosed based on physical examination and findings on chest ultrasound. Hypoalbuminemia is diagnosed based on low serum albumin levels. Patients are treated with steroids, antimalarials, diuretics, and antibiotics. The patient's symptoms improved and complications resolved. Conclusion: SLE is a complex disease that can cause a variety of serious complications. Early diagnosis and treatment of these complications are essential to improve the patient's prognosis. This case shows that SLE can cause a variety of serious complications, including lupus nephritis, CAP, bilateral pleural effusion, pericardial effusion, and hypoalbuminemia. Early diagnosis and treatment of these complications are essential to improve the patient's prognosis.
Hyperhomocysteinemia in Chronic Kidney Disease: A Meta-Analysis Faurin, Muthia; Deka Viotra
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 8 No. 12 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v8i12.1133

Abstract

Background: Hyperhomocysteinemia, an elevated level of homocysteine in the blood, has been implicated in the progression of chronic kidney disease (CKD). This meta-analysis aims to comprehensively evaluate the association between hyperhomocysteinemia and CKD and its potential impact on clinical outcomes. Methods: This study systematically searched electronic databases (PubMed, Embase, Cochrane Library) for studies published between 2018 and 2024 investigating the relationship between hyperhomocysteinemia and CKD. Studies reporting data on the association between hyperhomocysteinemia and CKD progression, cardiovascular events, or mortality were included. We extracted relevant data and performed a meta-analysis using random-effects models. Results: The meta-analysis included 25 studies comprising 5,672 patients with CKD. Hyperhomocysteinemia was significantly associated with an increased risk of CKD progression (pooled odds ratio [OR] 1.85, 95% confidence interval [CI] 1.52-2.24), cardiovascular events (pooled OR 1.63, 95% CI 1.31-2.02), and all-cause mortality (pooled OR 1.48, 95% CI 1.17-1.87) in CKD patients. Subgroup analyses revealed a consistent association across different CKD stages and etiologies. Conclusion: Hyperhomocysteinemia is an independent risk factor for CKD progression, cardiovascular events, and mortality. Monitoring and managing hyperhomocysteinemia may represent a potential therapeutic target to improve outcomes in CKD patients.